Access Bio Launches Full-Scale Entry into Digital Healthcare with Acquisition of US-Based CuraPatient

PharmGen Science announced on the 12th that Access Bio, a global in vitro diagnostics company in which it holds the largest stake, has secured new shares in the U.S. digital healthcare specialist company CuraPatients and is set to actively enter the digital healthcare business.

Photo by Curepatient

CuraPatients, located in California, USA, is a company that owns an artificial intelligence (AI)-based Software as a Service (SaaS) solution. It is the only healthcare company in the U.S. to have obtained the 'High' and 'Agency Wide' ratings in the Federal Risk and Authorization Management Program (FedRAMP) certification granted by the U.S. federal government.

The company explained, "This means that only CuraPatients can access patient information across various agencies within the U.S. federal government," adding, "This collaboration will enable us to secure competitiveness in the U.S. public sector digital healthcare service field." Additionally, since CuraPatients provides vaccination and chronic disease patient scheduling services to the largest pharmacy chain in the U.S., it is expected that its business network can also be utilized in the private sector.

CuraPatients possesses a healthcare platform that optimizes medical service scheduling and hospital medical staff utilization using ChatGPT, and based on this, offers medical appointment services through its mobile application (app) 'Othena.' Access Bio aims to maximize synergy through collaboration by leveraging its diverse diagnostic product portfolio.

An Access Bio representative stated, "First, we plan to use CuraPatients' appointment app as a new distribution channel for selling and supplying our products," and added, "In the future, we plan to promote collaboration with CuraPatients with the goal of building a one-stop integrated solution platform covering prevention, diagnosis, prescription, and treatment."